Viatris Amends Material Agreement Filing (8-K/A)

Ticker: VTRS · Form: 8-K/A · Filed: Jan 30, 2024 · CIK: 1792044

Complexity: simple

Sentiment: neutral

Topics: amendment, material-agreement, corporate-action

TL;DR

**Viatris just updated a key agreement filing, watch for details.**

AI Summary

Viatris Inc. filed an 8-K/A on January 30, 2024, amending a previous filing from October 1, 2023. This amendment relates to an "Entry into a Material Definitive Agreement" and "Financial Statements and Exhibits." While the specific details of the agreement are not disclosed in this summary, the filing indicates a significant contractual event that required an update to their public disclosures. This matters to investors as material agreements can impact Viatris's future revenue, expenses, and strategic direction, potentially affecting stock valuation.

Why It Matters

This amendment signals a significant contractual development for Viatris, which could influence its financial performance and strategic outlook, directly impacting shareholder value.

Risk Assessment

Risk Level: medium — The filing indicates a material agreement without disclosing specifics, creating uncertainty about its potential positive or negative impact on the company.

Analyst Insight

Investors should monitor Viatris's subsequent filings or press releases for specific details regarding the 'Material Definitive Agreement' to understand its financial implications and strategic impact.

Key Players & Entities

FAQ

What is the purpose of Viatris Inc.'s 8-K/A filing dated January 30, 2024?

The 8-K/A filing is an amendment (Amendment No. 1) to a previous Current Report, specifically addressing 'Entry into a Material Definitive Agreement' and 'Financial Statements and Exhibits' related to an event reported on October 1, 2023.

What was the original date of the earliest event reported that this 8-K/A amends?

The earliest event reported in the original filing, which this 8-K/A amends, occurred on October 1, 2023.

What is Viatris Inc.'s trading symbol and on which exchange is its common stock registered?

Viatris Inc.'s common stock trades under the symbol VTRS and is registered on The NASDAQ Stock Market.

What is the business address and phone number of Viatris Inc. as listed in the filing?

Viatris Inc.'s business address is 1000 Mylan Boulevard, Canonsburg, Pennsylvania, 15317, and its telephone number is (724) 514-1800.

What was Viatris Inc.'s former company name and when did the name change occur?

Viatris Inc.'s former company name was Upjohn Inc., and the date of the name change was October 23, 2019.

Filing Stats: 1,229 words · 5 min read · ~4 pages · Grade level 13.3 · Accepted 2024-01-30 16:40:59

Key Financial Figures

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This 8-K Amendment contains "forward-looking statements". These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, Viatris' completion of its obligations under the Transaction Agreement. Forward-looking statements may often be identified by the use of words such as "will", "may", "could", "should", "project", "believe", "anticipate", "expect", "plan", "estimate", "forecast", "potential", "pipeline", "intend", "continue", "target", "seek" and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the Transaction not being completed on the expected timelines or at all; the risk that the conditions set forth in the agreements with respect to the Transaction will not be satisfied or waived; failure to realize the total transaction value for the Transaction and/or the expected proceeds for the Transaction, including as a result of any purchase price adjustment or a failure to achieve any conditions to the payment of any contingent consideration; the possibility that the Company may be unable to realize the intended benefits of, or achieve the intended goals or outlooks with respect to, the Transaction, within the expected timeframe or at all; goodwill or other impairment charges or other losses related to the divestiture or sale of businesses or assets (including the Transaction). For more detailed information on the risks and uncertainties associated with Viatris, see the risks described in Part I, Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2022, as amended, and our other filings with the SEC. You can ac

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 2.1 Transaction Agreement, dated as of January 29, 2024, by and among Cooper Consumer Health SAS, Cooper Consumer Health IT S.r.l., Viatris Inc., Viatris Italia S.r.l. and Ipex AB* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Annexes, schedules and/or exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Viatris agrees to furnish supplementally a copy of any omitted attachment to the SEC upon request. - 3 - SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viatris Inc. By: /s/ Brian Roman Brian Roman Global General Counsel Date: January 30, 2024 - 4 -

View Full Filing

View this 8-K/A filing on SEC EDGAR

View on Read The Filing